Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010
Links shared publicly online about this topic.
- 636total visits
Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010
View full resource at pfizer.mediaroom.com
Tags: Vaccination, Pneumococcal Vaccine, FDA, Vaccine, Prevnar, Pfizer
Most Recently Shared on December 22, 2010 at 7:50 pm By:
Pfizer submits applications to FDA and EMA for use of its pneumococcal conjugate vaccine in adults 50 and older: http://bit.ly/g6Z07K
Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease
news-medical.net — “Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.” View full resource at news-medical.net
Most Recently Shared on December 23, 2010 at 10:36 am By:
Meningitis News: Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease: Pfiz... http://bit.ly/eq2rKO
Advertisement
